ReviewActa pharmaceutica Sinica. B2022
Therapeutic potential of traditional Chinese medicine for the treatment of NAFLD: A promising drug
Review in Acta pharmaceutica Sinica. B, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 47 citations in OpenAlex.
- Review
- Hu Gan Tang Ameliorates Lipid Deposition of Metabolic-Associated Fatty Liver Disease by Promoting Autophagy Through the AMPK/mTOR Pathway.Chemistry & biodiversity · 2026Article
- Qushi Huoxue ointment ameliorates metabolic associated steatotic liver disease through autophagy activation and ferroptosis inhibition.World journal of hepatology · 2026Article
- Hyperoside modulates bile acid and fatty acid metabolism, presenting a potentially promising treatment for non-alcoholic fatty liver disease.Journal of advanced research · 2026Article
- Analysis of the biological mechanism of Gurigumu-13 in the treatment of non-alcoholic fatty liver disease based on network pharmacology.Hereditas · 2026Article
- Total flavonoids of Potentilla discolor alleviate type 2 diabetes by regulating gut microbiota and endogenous metabolites.Frontiers in microbiology · 2026Article
- Research Progress on Nanoformulations Based on Active Components from Traditional Chinese Medicine for MASLD.International journal of nanomedicine · 2026Review
- Transdermal Delivery of Chinese Medicinal Formula Mitigates Pediatric Constipation by Modulating Intestinal Endocrine and Metabolic Homeostasis.Biomaterials research · 2026Article
- Shengdihuang Xiyangshen Zhimu Cangzhu Formula Improves Hepatic Glycogen Synthesis via the JNK/c-Jun/IRS1/GSK3β Signaling Pathway.Journal of diabetes research · 2026Article
- Pathological characteristics of traditional Chinese medicine Shi Zheng and related therapeutic formula, effective compounds: a general review.Chinese medicine · 2025Review
- Deciphering the hepatoprotective mechanism of Sarcopyramis nepalensis wall against non-alcoholic fatty liver disease by network pharmacology and experimental validation.Scientific reports · 2025Article
- Flavone C-Glycosides fromNutrients · 2025Article
- 3,3'-Diindolylmethane Ameliorates Metabolism Dysfunction-Associated Fatty Liver Disease via AhR/p38 MAPK Signaling.Nutrients · 2025Article
- Targeting the gut microbiota and lipid metabolism: potential mechanisms of natural products for the treatment of non-alcoholic fatty liver disease.Frontiers in pharmacology · 2025Review
- Potential of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease: A promising future.World journal of gastroenterology · 2024Article
- A systematic, updated review of Xuezhikang, a domestically developed lipid-lowering drug, in the application of cardiovascular diseases.Acta pharmaceutica Sinica. B · 2024Review
- Fanlian Huazhuo Formula alleviates high-fat diet-induced non-alcoholic fatty liver disease by modulating autophagy and lipid synthesis signaling pathway.World journal of gastroenterology · 2024Article
- Lian-Mei-Yin formula alleviates diet-induced hepatic steatosis by suppressing Yap1/FOXM1 pathway-dependent lipid synthesis.Acta biochimica et biophysica Sinica · 2024Article
- Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies.Chinese medicine · 2024Review
- The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.International journal of biological sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive accumulation of hepatic lipids and metabolic stress-induced liver injury. There are currently no approved effective pharmacological treatments for NAFLD. Traditional Chinese medicine (TCM) has been used for centuries to treat patients with chronic liver diseases without clear disease types and mechanisms. More recently, TCM has been shown to have unique advantages in the treatment of NAFLD. We performed a systematic review of the medical literature published over the last two decades and found that many TCM formulas have been reported to be beneficial for the treatment of metabolic dysfunctions, including
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.